• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical and Radiographic Benefit of a Patient With Metastatic Non-Small Cell Lung Cancer Harboring an Fusion Through Use of EGFR Tyrosine Kinase Inhibitors.

作者信息

Guimaraes-Young Amy, Davies Kurtis D, Trevisan Patricia, Nijmeh Hala, Haag Mary, Aisner Dara L, Patil Tejas

机构信息

Department of Pathology, University of Colorado School of Medicine, Aurora, CO.

Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO.

出版信息

JCO Precis Oncol. 2024 Dec;8:e2400526. doi: 10.1200/PO-24-00526. Epub 2024 Dec 5.

DOI:10.1200/PO-24-00526
PMID:39637337
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11634169/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e199/11634169/b98ad09dc5c0/po-8-e2400526-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e199/11634169/da57e201bbd9/po-8-e2400526-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e199/11634169/9f4c82b62fd5/po-8-e2400526-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e199/11634169/b98ad09dc5c0/po-8-e2400526-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e199/11634169/da57e201bbd9/po-8-e2400526-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e199/11634169/9f4c82b62fd5/po-8-e2400526-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e199/11634169/b98ad09dc5c0/po-8-e2400526-g003.jpg

相似文献

1
Clinical and Radiographic Benefit of a Patient With Metastatic Non-Small Cell Lung Cancer Harboring an Fusion Through Use of EGFR Tyrosine Kinase Inhibitors.一名携带 融合的转移性非小细胞肺癌患者使用表皮生长因子受体酪氨酸激酶抑制剂的临床和影像学获益
JCO Precis Oncol. 2024 Dec;8:e2400526. doi: 10.1200/PO-24-00526. Epub 2024 Dec 5.
2
Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.非小细胞肺癌脑转移的治疗。
Int J Mol Sci. 2021 Jan 8;22(2):593. doi: 10.3390/ijms22020593.
3
Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.克唑替尼耐药的 ROS1 融合肺肿瘤中卡博替尼和吉非替尼的联合作用。
Cancer Sci. 2018 Oct;109(10):3149-3158. doi: 10.1111/cas.13752. Epub 2018 Sep 11.
4
The Treatment of a Novel Epidermal Growth Factor Receptor (EGFR)-GRB2 Genetic Mutation Using Osimertinib in Metastatic Non-Small Cell Lung Cancer.奥希替尼治疗转移性非小细胞肺癌中一种新型表皮生长因子受体（EGFR）-GRB2基因突变
Cureus. 2023 Apr 24;15(4):e38059. doi: 10.7759/cureus.38059. eCollection 2023 Apr.
5
[A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker].[非小细胞肺癌（NSCLC）治疗的新视角。阿法替尼的作用：一种口服不可逆的表皮生长因子受体（ErbB）家族阻滞剂]
Bull Cancer. 2014 Jun;101(6):647-52. doi: 10.1684/bdc.2014.1986.
6
Efficacy of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Metastatic Non-Small Cell Lung Cancer Patients with Poor Performance Status and Epidermal Growth Factor Receptor Mutations: Findings from the Japanese Lung Cancer Registry Database.表皮生长因子受体酪氨酸激酶抑制剂对体能状态差且表皮生长因子受体突变的转移性非小细胞肺癌患者的疗效：来自日本肺癌登记数据库的研究结果
Clin Lung Cancer. 2024 Jun;25(4):336-346.e2. doi: 10.1016/j.cllc.2024.01.005. Epub 2024 Feb 2.
7
Adenocarcinoma Harboring Fusion Treated With Osimertinib: A Case Report.奥希替尼治疗携带融合基因的腺癌：一例报告
JTO Clin Res Rep. 2024 Feb 19;5(4):100652. doi: 10.1016/j.jtocrr.2024.100652. eCollection 2024 Apr.
8
Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan.表皮生长因子受体酪氨酸激酶抑制剂治疗非小细胞肺癌罕见 EGFR 突变：来自台湾的真实世界数据。
Thorac Cancer. 2023 Jan;14(1):12-23. doi: 10.1111/1759-7714.14537. Epub 2022 Nov 24.
9
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring Class 3 Mutations.表皮生长因子受体酪氨酸激酶抑制剂在携带3类突变的非小细胞肺癌中的临床及临床前活性
JCO Precis Oncol. 2024 Dec;8:e2400240. doi: 10.1200/PO.24.00240. Epub 2024 Dec 5.
10
Progastrin-Releasing Peptide Precursor and Neuron-Specific Enolase Predict the Efficacy of First-Line Treatment with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors Among Non-Small-Cell Lung Cancer Patients Harboring EGFR Mutations.胃泌素释放肽前体和神经元特异性烯醇化酶可预测表皮生长因子受体（EGFR）酪氨酸激酶抑制剂对携带EGFR突变的非小细胞肺癌患者一线治疗的疗效。
Cancer Manag Res. 2021 Jan 5;12:13607-13616. doi: 10.2147/CMAR.S285121. eCollection 2020.

本文引用的文献

1
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.曲妥珠单抗-德鲁替康用于转移性非小细胞肺癌患者（DESTINY-Lung01）：一项单臂、2 期临床试验中 HER2 过表达队列的主要结果。
Lancet Oncol. 2024 Apr;25(4):439-454. doi: 10.1016/S1470-2045(24)00064-0.
2
Adenocarcinoma Harboring Fusion Treated With Osimertinib: A Case Report.奥希替尼治疗携带融合基因的腺癌：一例报告
JTO Clin Res Rep. 2024 Feb 19;5(4):100652. doi: 10.1016/j.jtocrr.2024.100652. eCollection 2024 Apr.
3
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.
曲妥珠单抗-德鲁替康在 HER2 表达的实体瘤患者中的疗效和安全性：来自 DESTINY-PanTumor02 Ⅱ期试验的初步结果。
J Clin Oncol. 2024 Jan 1;42(1):47-58. doi: 10.1200/JCO.23.02005. Epub 2023 Oct 23.
4
family fusions are recurrent and actionable oncogenic targets across cancer types.家族融合是多种癌症类型中反复出现且可作用的致癌靶点。
Front Oncol. 2023 Apr 24;13:1115405. doi: 10.3389/fonc.2023.1115405. eCollection 2023.
5
Evolving Treatment Landscape of -mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond.-突变型非小细胞肺癌不断演变的治疗格局：曲妥珠单抗德鲁替康及其他。
Cancers (Basel). 2023 Feb 17;15(4):1286. doi: 10.3390/cancers15041286.
6
UniProt: the Universal Protein Knowledgebase in 2023.UniProt：2023 年的通用蛋白质知识库。
Nucleic Acids Res. 2023 Jan 6;51(D1):D523-D531. doi: 10.1093/nar/gkac1052.
7
Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial.曲妥珠单抗-德鲁替康用于人表皮生长因子受体 2 低表达的胃或胃食管结合部腺癌患者：一项 II 期临床试验的探索性队列研究结果。
J Clin Oncol. 2023 Feb 1;41(4):816-825. doi: 10.1200/JCO.22.00575. Epub 2022 Nov 15.
8
Real-world efficacy and safety of mobocertinib in exon 20 insertion-mutated lung cancer.莫博替尼在20号外显子插入突变型肺癌中的真实世界疗效与安全性
Front Oncol. 2022 Sep 20;12:1010311. doi: 10.3389/fonc.2022.1010311. eCollection 2022.
9
EGFR-RAD51 fusion in lung adenocarcinoma with systemic and intracranial response to osimertinib: A case report and review of the literature.肺腺癌中EGFR-RAD51融合对奥希替尼有全身和颅内反应：一例报告及文献复习
Lung Cancer. 2022 Apr;166:94-97. doi: 10.1016/j.lungcan.2022.02.006. Epub 2022 Feb 18.
10
Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study.奥希替尼治疗伴有无症状脑转移的晚期表皮生长因子受体（EGFR）突变型肺腺癌：一项开放标签、三臂、II期试点研究。
Neurooncol Adv. 2021 Dec 27;4(1):vdab188. doi: 10.1093/noajnl/vdab188. eCollection 2022 Jan-Dec.